Vivus's erectile dysfunction candidate meets goals of first Phase III study
This article was originally published in Scrip
Vivus's phosphodiesterase-5 inhibitor (PDE-5) avanafil has been shown to improve erectile function in the first of the drug's four pivotal Phase III studies for the treatment of erectile dysfunction (ED).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.